PASG

SEC source: 0001787297-22-000006 · primary_doc.xml · derivative · entry 1

Toernsen Monika Maria · CIK 0001873385 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,000

Underlying: Common Stock · 101,000 shares

Expires 2032-02-09

F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001787297-22-000002 · primary_doc.xml · derivative · entry 1

Goldsmith Bruce A · CIK 0001500322 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2032-02-09

F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001787297-22-000005 · primary_doc.xml · derivative · entry 1

Salinas Eliseo Oreste · CIK 0001435756 · Chief Res. & Develop Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,500

Underlying: Common Stock · 157,500 shares

Expires 2032-02-09

F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001787297-22-000004 · primary_doc.xml · derivative · entry 2

Fotopoulos Alexandros · CIK 0001799814 · Chief Technical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,900

Underlying: Common Stock · 163,900 shares

Expires 2032-02-09

F2 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001787297-22-000001 · primary_doc.xml · derivative · entry 2

Cale Edgar B. · CIK 0001799783 · GC and Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,000

Underlying: Common Stock · 106,000 shares

Expires 2032-02-09

F2 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001415889-24-003637 · form4-02142024_120249.xml · derivative · entry 5

Forman Mark S · CIK 0001922353 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F5 · derivative.exercise_date: 1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F5 · derivative.expiration_date: 1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001415889-24-003637 · form4-02142024_120249.xml · derivative · entry 4

Forman Mark S · CIK 0001922353 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-02-09

F4 · derivative.exercise_date: The stock option vests as of 1/48 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0000947871-22-000090 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 6,634,723

F1 · price: These shares of the Issuer's common stock ("Shares") were purchased in a block order at price of $5.60.

F2 · ownership.nature: The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationship, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII.

F3 · ownership.nature: Each of GP VII and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-22-000507 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 6,316,423

F1 · shares: On January 24, 2022, the Reporting Person filed a Form 4 which inadvertently reported the incorrect number and purchase price of shares of the Issuer's common stock ("Shares") purchased by the reporting person on January 20, 2022. This amendment provides the correct number and purchase price of the Shares purchased and correctly reflects the number of Shares owned by the Reporting Person following such purchase.

F1 · price: On January 24, 2022, the Reporting Person filed a Form 4 which inadvertently reported the incorrect number and purchase price of shares of the Issuer's common stock ("Shares") purchased by the reporting person on January 20, 2022. This amendment provides the correct number and purchase price of the Shares purchased and correctly reflects the number of Shares owned by the Reporting Person following such purchase.

F2 · price: These Shares were purchased in a block order at a price of $5.00.

F1 · balance_after: On January 24, 2022, the Reporting Person filed a Form 4 which inadvertently reported the incorrect number and purchase price of shares of the Issuer's common stock ("Shares") purchased by the reporting person on January 20, 2022. This amendment provides the correct number and purchase price of the Shares purchased and correctly reflects the number of Shares owned by the Reporting Person following such purchase.

F3 · ownership.nature: The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationship, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII.

F4 · ownership.nature: Each of GP VII and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-22-000086 · ownership.xml · nonDerivative · entry 3

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 6,265,623

F4 · price: These Shares were purchased in a block order at price of $5.11.

F2 · ownership.nature: The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationship, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII.

F5 · ownership.nature: Each of GP VII and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-22-000086 · ownership.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 6,222,323

F3 · price: These Shares were purchased in a block order at price of $5.46.

F2 · ownership.nature: The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationship, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII.

F5 · ownership.nature: Each of GP VII and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-22-000086 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 6,107,623

F1 · price: These shares of the Issuer's common stock ("Shares") were purchased in a block order at price of $5.60.

F2 · ownership.nature: The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationship, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII.

F5 · ownership.nature: Each of GP VII and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-22-000055 · ownership.xml · nonDerivative · entry 3

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 6,097,323

F4 · price: These Shares were purchased in a block order at price of $5.52.

F2 · ownership.nature: The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII"), is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationship, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII.

F5 · ownership.nature: Each of GP VII and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-22-000055 · ownership.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 6,055,523

F3 · price: These Shares were purchased in a block order at price of $5.65.

F2 · ownership.nature: The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII"), is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationship, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII.

F5 · ownership.nature: Each of GP VII and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-22-000055 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 5,955,523

F1 · price: These shares of the Issuer's common stock ("Shares") were purchased in a block order at price of $5.53.

F2 · ownership.nature: The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII"), is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationship, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII.

F5 · ownership.nature: Each of GP VII and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001209191-21-069101 · doc4.xml · derivative · entry 4

Quigley Jill M. · CIK 0001799780 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,626

Underlying: Common Stock · 60,782 shares

Expires 2029-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option vests as to 25% of the total shares on May 8, 2020 and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on May 8, 2023 subject to the reporting person's provision of service to the issuer on each vesting date.

SEC source: 0001209191-21-069101 · doc4.xml · derivative · entry 3

Quigley Jill M. · CIK 0001799780 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,729

Underlying: Common Stock · 11,193 shares

Expires 2029-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vested as to 25% of the total shares on November 12, 2019 and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on November 12, 2022, subject to the reporting person's provision of service to the issuer on each vesting date.

SEC source: 0001209191-21-069101 · doc4.xml · nonDerivative · entry 1

Quigley Jill M. · CIK 0001799780 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 368,754

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 367,259 of common stock, of which 88,488 shares are unvested and subject to repurchase by the Issuer if the reporting person ceases to provide services to the Issuer prior to the vesting of the shares.

F2 · balance_after: Includes 1,495 shares acquired under the 2020 Employee Stock Purchase Plan on May 14, 2021.

SEC source: 0001209191-21-053365 · doc4.xml · derivative · entry 1

King Simona · CIK 0001879312 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 360,000

Underlying: Common Stock · 360,000 shares

Expires 2031-08-22

F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on August 23, 2022, then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on August 23, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001415889-24-003637 · form4-02142024_120249.xml · derivative · entry 3

Forman Mark S · CIK 0001922353 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 130,000 shares

Expires 2031-08-15

F3 · derivative.exercise_date: The stock option vests as to 25% of the total shares on August 16, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-047616 · doc4.xml · derivative · entry 2

Toernsen Monika Maria · CIK 0001873385 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F3 · derivative.exercise_date: 1/4 of the RSUs will vest annually on September 15, 2022, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F3 · derivative.expiration_date: 1/4 of the RSUs will vest annually on September 15, 2022, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-047616 · doc4.xml · derivative · entry 1

Toernsen Monika Maria · CIK 0001873385 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2031-07-18

F1 · derivative.exercise_date: The option vests as to 25% of the total shares on July 19, 2022, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on July 19, 2024, subject to the Reporting Person's provision of service to the issuer on each vesting date.

SEC source: 0001209191-21-036621 · doc4.xml · derivative · entry 1

Porter Derrell · CIK 0001706400 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,836

Underlying: Common Stock · 33,836 shares

Expires 2031-05-26

F1 · derivative.exercise_date: The stock option vests as of 1/36 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-036629 · doc4.xml · derivative · entry 1

Yamada Tadataka · CIK 0001402530 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,918

Underlying: Common Stock · 16,918 shares

Expires 2031-05-26

F1 · derivative.exercise_date: The stock option vests as of 1/12 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-036622 · doc4.xml · derivative · entry 1

Ratcliffe Liam · CIK 0001547100 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,918

Underlying: Common Stock · 16,918 shares

Expires 2031-05-26

F1 · derivative.exercise_date: The stock option vests as of 1/12 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-036616 · doc4.xml · derivative · entry 1

Countouriotis Athena · CIK 0001571469 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,918

Underlying: Common Stock · 16,918 shares

Expires 2031-05-26

F1 · derivative.exercise_date: The stock option vests as of 1/12 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-036628 · doc4.xml · derivative · entry 1

Islam Saqib · CIK 0001575408 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,918

Underlying: Common Stock · 16,918 shares

Expires 2031-05-26

F1 · derivative.exercise_date: The stock option vests as of 1/12 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-036630 · doc4.xml · derivative · entry 1

Woiwode Thomas · CIK 0001619294 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,918

Underlying: Common Stock · 16,918 shares

Expires 2031-05-26

F1 · derivative.exercise_date: The stock option vests as of 1/12 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-036625 · doc4.xml · derivative · entry 1

Kapadia Sandip · CIK 0001677141 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,918

Underlying: Common Stock · 16,918 shares

Expires 2031-05-26

F1 · derivative.exercise_date: The stock option vests as of 1/12 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-036754 · doc4.xml · derivative · entry 1

GOWEN MAXINE · CIK 0001280044 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,542

Underlying: Common Stock · 4,542 shares

Expires 2031-05-26

F1 · derivative.exercise_date: The stock option vests as of 1/12 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-035051 · doc4.xml · nonDerivative · entry 1

Goldsmith Bruce A · CIK 0001500322 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,983

F1 · balance_after: Includes 2020 Employee Stock Purchase Plan allocations of 1,495 shares that occurred since the date of the reporting person's last ownership report.

SEC source: 0001209191-21-035059 · doc4.xml · nonDerivative · entry 1

Morris Richard Steven · CIK 0001432303 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,454

F1 · balance_after: Includes 2020 Employee Stock Purchase Plan allocations of 1,495 shares that occurred since the date of the reporting person's last ownership report.

SEC source: 0001209191-21-034185 · doc4.xml · derivative · entry 1

Fotopoulos Alexandros · CIK 0001799814 · Chief Technical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F2 · derivative.exercise_date: 1/4 of the RSUs will vest on June 15, 2022, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F2 · derivative.expiration_date: 1/4 of the RSUs will vest on June 15, 2022, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-023476 · doc4.xml · derivative · entry 3

Salinas Eliseo Oreste · CIK 0001435756 · Chief Res. & Develop Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F4 · derivative.exercise_date: 1/4 of the RSUs will vest on June 15, 2022, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F4 · derivative.expiration_date: 1/4 of the RSUs will vest on June 15, 2022, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-023476 · doc4.xml · derivative · entry 2

Salinas Eliseo Oreste · CIK 0001435756 · Chief Res. & Develop Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F3 · derivative.exercise_date: The RSUs shall vest as to 33.33% of the total shares each on June 15, 2021, September 15, 2021 and December 15, 2021, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F3 · derivative.expiration_date: The RSUs shall vest as to 33.33% of the total shares each on June 15, 2021, September 15, 2021 and December 15, 2021, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-023476 · doc4.xml · derivative · entry 1

Salinas Eliseo Oreste · CIK 0001435756 · Chief Res. & Develop Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 275,000

Underlying: Common Stock · 275,000 shares

Expires 2031-03-22

F1 · derivative.exercise_date: The option vests as to 25% of the total shares on March 22, 2022, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on March 22, 2025, subject to the reporting person's provision of service to the issuer on each vesting date.

SEC source: 0001209191-21-021616 · doc4.xml · derivative · entry 4

Romano Gary · CIK 0001799779 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,821

Underlying: Common Stock · 10,000 shares

Expires 2029-10-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option vests as to 25% of the total shares on August 20, 2020 and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on August 20, 2023 subject to the reporting person's provision of service to the issuer on each vesting date. The option provides for an early-exercise provision and is exercisable as to unvested shares, subject to the issuer's right of repurchase.

SEC source: 0001209191-21-021616 · doc4.xml · nonDerivative · entry 3

Romano Gary · CIK 0001799779 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.65 to $22.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-21-021616 · doc4.xml · nonDerivative · entry 2

Romano Gary · CIK 0001799779 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,617

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.60 to $21.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-21-021616 · doc4.xml · nonDerivative · entry 1

Romano Gary · CIK 0001799779 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-012828 · doc4.xml · derivative · entry 1

GOWEN MAXINE · CIK 0001280044 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,836

Underlying: Common Stock · 33,836 shares

Expires 2031-02-17

F1 · derivative.exercise_date: The stock option vests as of 1/36 of the total shares monthly beginning on March 18, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-012170 · doc4.xml · derivative · entry 1

Quigley Jill M. · CIK 0001799780 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Common Stock · 105,000 shares

Expires 2031-02-15

F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 16, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-012160 · doc4.xml · derivative · entry 1

Romano Gary · CIK 0001799779 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Common Stock · 105,000 shares

Expires 2031-02-15

F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 16, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-012156 · doc4.xml · derivative · entry 2

Goldsmith Bruce A · CIK 0001500322 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 262,000

Underlying: Common Stock · 262,000 shares

Expires 2031-02-15

F2 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 16, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-012169 · doc4.xml · derivative · entry 2

Morris Richard Steven · CIK 0001432303 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2031-02-15

F2 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 16, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-012158 · doc4.xml · derivative · entry 2

Cale Edgar B. · CIK 0001799783 · GC and Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,997

Underlying: Common Stock · 170,997 shares

Expires 2031-02-15

F2 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 16, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-012154 · doc4.xml · derivative · entry 2

Fotopoulos Alexandros · CIK 0001799814 · Chief Technical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Common Stock · 105,000 shares

Expires 2031-02-15

F2 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 16, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-004949 · doc4.xml · nonDerivative · entry 1

Quigley Jill M. · CIK 0001799780 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 295,284

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F3 · balance_after: Represents 295,284 of common stock, of which 148,534 shares are unvested and subject to repurchase by the Issuer if the reporting person ceases to provide services to the Issuer prior to the vesting of the shares.

SEC source: 0001209191-21-003921 · doc4.xml · nonDerivative · entry 1

Quigley Jill M. · CIK 0001799780 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 296,584

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F3 · balance_after: Represents 296,584 shares of common stock, of which 148,534 shares are unvested and subject to repurchase by the Issuer if the reporting person ceases to provide services to the Issuer prior to the vesting of the shares.

F4 · balance_after: Includes 1,388 shares acquired under the 2020 Employee Stock Purchase Plan on November 15, 2020.

SEC source: 0001209191-20-021188 · doc4.xml · nonDerivative · entry 1

Countouriotis Athena · CIK 0001571469 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,900

F1 · price: Represents the weighted average purchase price per share. The shares were purchased at prices ranging from $14.79 to $15.00 per share. Full information regarding the number of shares purchased at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.